Guggenheim Reaffirms Buy on Oruka After Strong ORKA-001 Psoriasis Data
Oruka’s ORKA-001 outperformed Skyrizi on complete clearance in Phase 2b. Analysts model $7B peak sales and maintain bullish ratings.
Oruka’s ORKA-001 outperformed Skyrizi on complete clearance in Phase 2b. Analysts model $7B peak sales and maintain bullish ratings.
Analysts called the readout in line with base case. Next tests: 52-week EVERLAST-A in December and EVERLAST-B data in Q4.
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Piper Sandler gives Oruka Therapeutics an Overweight rating, highlighting its unique antibody portfolio, ORKA-001 validation, and a promising 2026 catalyst-rich year.
Guggenheim starts coverage of Oruka Therapeutics with Buy rating and $60 target, praising its longer-acting antibody drugs for chronic inflammation treatment.
Oruka Therapeutics shares jump 30% as analysts predict gains following competitor MoonLake's Phase 3 results.